BIOMARKER SST2 AS AN EARLY PREDICTOR OF ACUTE RENAL INJURY IN PATIENTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION.

One of the serious complications of ST-segment elevation myocardial infarction (STEMI) is acute kidney injury (AKI). Promising in this respect is the stimulating growth factor sST2. A sharp increase of ST2 level in case of injury is accompanied by inhibition of IL-33 favorable antihypertrophic effects. The purpose - to analyze the prognostic significance of sST2 biomarker in identifying the risk of AKI development in patients with STEMI. The study included 103 patients with STEMI, of which 75 patients were men (72.8%) whose mean age was (61.85±12.23) years. Patients were hospitalized at the intensive care unit during the first day of the disease. Patients were subjected selective coronary angiography (SCAG) with subsequent stenting of the infarct-related artery. Criteria for inclusion into the study concerned patients with STEMI, who arrived in the hospital during 24 hours after the onset of the symptoms and agreed to participate in the study. The level of sST2 was determined during the first 24 hours after the event. In multivariate regression analysis, we found that sST2 and blood glucose are the only significant predictors of acute kidney injury during the first 48 hours (R2=0.437, P<0.001) among the parameters included into the study, such as the NT-pro BNP biomarker, ejection fraction, E/A ratio, end diastolic volume and hemoglobin level. The first time a prognostic model has developed and this model used simple, but significant factors. The role of the biomarker ST2 in the early stratification of reduced kidney function in patients with STEMI suggests the development of AKI.